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We present the first quantitative analysis of atypical teratoid rhabdoid tumors (ATRT)
in adults, including two patients from our own institutions. These are of interest as one
occurred during pregnancy and one is a long-term survivor. Our review of pathological
findings of 50 reported cases of adult ATRT leads us to propose a solely ectodermal
origin for the tumor and that epithelial–mesenchymal transition (EMT) is a defining feature. Thus, the term ATRT may be misleading. Our review of clinical findings shows that
ATRT tends to originate in mid-line structures adjacent to the CSF, leading to a high rate
of leptomeningeal dissemination. Thus, we hypothesize that residual undifferentiated
ectoderm in the circumventricular organs, particularly the pituitary and pineal glands,
is the most common origin for these tumors. We note that if growth is not arrested
soon after diagnosis, or after the first relapse/progression, death is almost universal.
While typically rapidly fatal (as in our first case), long-term remission is possible (as in
our second). Significant predictors of prognosis were the extent of resection and the
use of chemotherapy. Glial differentiation (GFAP staining) was strongly associated with
leptomeningeal metastases (chi-squared p = 0.02) and both predicted markedly worse
outcomes. Clinical trials including adults are rare. ATRT is primarily a disease of infancy
and radiotherapy is generally avoided in those aged less than 3 years old. Treatment
options in adults differ from infants in that cranio-spinal irradiation is a viable adjunct
to systemic chemotherapy in the adult population. Given the grave prognosis, this
combined approach appears reasonable. As effective chemotherapy is likely to cause
myelosuppression, we recommend that stem-cell rescue be available locally.
Keywords: teratoma, rhabdoid tumor, adult, pregnancy, statistical data analysis, statistical data interpretation,
etiology
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1. INTRODUCTION

2. CASE REPORTS

1.1. History of ATRT

2.1. A Case in Pregnancy

ATRT, a cancer of the CNS, was christened by Rorke et al. in
1996, following a review of 52 pediatric cases (1). We may trace
the first appearance of the term “atypical teratoma” to four
decades earlier, where it was recognized to occur in the pineal
gland (2). The “atypical” refers descriptively to the “teratoid” part
of the tumor. This appears to show elements of two germ cell
layers (ectoderm, i.e., primitive neuroepithelial, epithelial, and
mesoderm, i.e., “rhabdoid”) but is otherwise quite different from
classical teratoid tumors. “Rhabdoid” (Greek, “rod-like”) refers to
the similarity, on microscopy, to tumors showing skeletal muscle
differentiation.
The biology of and treatment strategies for ATRT (focusing
on children) have been the subject of a recent, thorough review.
Although the prognosis in children has traditionally been dismal,
with few long-term survivors, developments over the last 10 years
have, at least for children, been encouraging (3). Recently, mutations in the chromatic remodeling complex SMARCB1 (and, as a
rare alternative, of SMARCA4) have been identified in the great
majority of cases of ATRT (4). Such mutations appear necessary
for the development of ATRT; no other consistent genetic abnormalities have been identified.

2.1.1. Presentation

Our first patient was a 29-year-old woman who developed
hoarseness during week 20 of her first pregnancy, which deteriorated over the subsequent 5 weeks. Over the course of 1 day, she
developed weakness of the right arm and leg. A CT performed
elsewhere showed the presence of an extra-axial left cerebellopontine mass. This was interpreted as a probable meningioma, so
further treatment was deferred.
At 35 weeks gestation, she developed status migrainosus and
worsening right leg weakness. Her voice had become weaker and
she coughed intermittently when swallowing. Paralysis of her
left vocal cord was demonstrated via laryngoscopy. Her MRIs at
this time are shown in Figures 1 and 2. A cesarean section was
performed in anticipation of neurosurgery and a healthy baby
boy was delivered.

2.1.2. Initial Treatment

A left retro-sigmoid craniotomy was performed. Pathology, showing loss of immunohistochemical staining for INI1, confirmed
ATRT. Her spinal MRI showed leptomeningeal metastases in the
cervical and thoracic cord. She rapidly developed hydrocephalus;
a shunt and Ommaya reservoir were placed 1 week after surgery.
Multimodal treatment was instituted. Systemic chemotherapy
involved two cycles (of 14 days) of ICE (ifosfamide, carboplatin,
etoposide). Following the second cycle, she developed pancytopenia and sepsis, and thereafter no further systemic treatment
was pursued.
Intrathecal chemotherapy was with liposomal cytarabine
50 mg via Ommaya every 2 weeks; she received 6 doses in total.
Intensity-modulated radiotherapy to the cerebellum was 54 Gy
in 30 fractions; conformal radiotherapy to the cord at C5–T6

1.2. ATRT in Adults

While ATRT is the most common malignant CNS tumor in
children aged <1, cases in adults (i.e., age >18) are rare—we
estimate <1/1,000,000 lifetime risk (5). As such, these patients
are presented in detail as case reports or in small case series. There
are no molecular markers recognized as unique to adults rather
than children; in both cases, loss of INI1 staining via immunohistochemistry (IHC) is considered sufficient for diagnosis in the
appropriate context.

1.3. Rhabdoid Tumors

ATRT is often described as analogous to “malignant rhabdoid
tumor of the kidney,” a tumor recognized since at least the early
1980s (6). Other CNS tumors with rhabdoid histology include the
“epithelioid glioblastoma with rhabdoid component” as well as
the “rhabdoid” variants of more common tumors: meningioma,
carcinoma, chordoma, and even sarcoma (7).

1.4. EMT

Epithelial–mesenchymal transition (EMT) was initially identified
as a phenomenon in developmental biology. The occurrence of
EMT in certain cancers has been suggested since 1978, although
it only began to receive widespread attention 10 years later (8).
The role of EMT in carcinogenesis has been the subject of an
extensive review (9). EMT appears to be crucial to the development and maintenance of a pool of slowly dividing, chemoresistant, “cancer stem cells.” We hypothesize that the “rhabdoid”
appearance of the tumors above reflects EMT.

Frontiers in Neurology | www.frontiersin.org

Figure 1 | First patient. MRI brain at time of diagnosis, 1.5 T. Images are
T1-weighted and Gd-enhanced. (A) Axial: heterogeneous extra-axial
enhancement is seen in the left cerebello-pontine angle, with some local
compression. (B) Coronal: enhancement is seen along the tentorium cerebelli
on the right, which is characteristic of leptomeningeal spread. The left
cerebellar lesion appears intraparenchymal.
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Figure 2 | First patient. MRIs of spine, 1.5 T, sagittal. (A) Gd-enhanced:
diffuse, nodular enhancement is seen throughout. This is striking dorsally and
at the conus medullaris. (B) T2-weighted: the thoracic cord is swollen with
intra-medullary edema. This appears to be a reaction to the surrounding
leptomeningeal tumor; there may also be an element of cord compression in
the thoracic cord. (C) Gd-enhanced: disease in the upper thoracic cord is
much improved following radiotherapy. Progression has occurred around the
untreated cord caudally. (D) T2-weighted: similarly, intra-medullary edema
has improved in the treated areas but worsened elsewhere.

Figure 3 | Second patient. MRIs of brain. Upper row (A–C): T1-weighted,
Gd-enhanced (magnetization-prepared rapid gradient-echo (MPRAGE)).
A suprasellar and interpeduncular lesion is seen with mixed solid and cystic
(lobulated) elements. There is heterogeneous enhancement of intermediate
intensity. Lower row (A,B): T1-weighted, Gd-enhanced. There is no
evidence of tumor recurrence. Smooth linear enhancement is present at the
resection site, which is consistent with the long-term changes seen
following surgery.

vertebral levels was 30 Gy in 10 fractions. Disease in the brain
and upper spinal cord improved overall with treatment, except for
one focus in the pre-pontine cistern which grew in a plaque-like
fashion.

5′ and 3′ splice sites from nucleotide 37 to 47,120 in the reference
sequence NT_011520.gbk (10). The mutation was described as
NM_003073.3: c.1148delC, NP_003064: p.P383fs*96.
Occurring in exon 9, this causes a SMARCB1 protein frame-shift
and the insertion of additional amino acids at the 3′ end of the
protein. This mutation is predicted to lead to inactivation of this
protein in the tumor.

2.1.3. Treatment at progression

In view of progressive weakness of the legs, she received an
additional 30 Gy in 10 fractions to the spinal cord at T12–L4.
Within a month of completing this treatment, she developed a
flaccid paraplegia with loss of bladder and bowel control and a
sensory level at T10. Her MRI confirmed progression (Figure 2).
Thereafter, she was cared for by Hospice and died 5 months following her initial surgery.

2.2.2. Initial Treatment

MRIs performed following surgery demonstrated a nodule in the
third ventricle that was believed to be persistent malignancy, as
well as a nodule in the upper lumbar spinal cord, most likely a sign
of leptomeningeal metastasis. Hence, cranio-spinal radiotherapy
was given at a dose of 36 Gy in 20 fractions. Localized boosts
were given to the primary site (20 Gy in 12 fractions) and the
lumbar spine (8 Gy in 4 fractions). This treatment was completed
3 months following his initial surgery.
He proceeded to receive chemotherapy using the St. Judes
ATRT protocol. This was developed for children aged >3 and
comprises 4 cycles of cisplatin with high-dose cyclophosphamide
and vincristine, with autologous peripheral blood stem-cell
transplantation (11). This took 5 months to complete.
Since completing treatment there has been no sign of residual/
recurrent disease at 2.5 years follow-up, clinically or on MRI, as
seen in Figure 3.
Since his initial resection, he has suffered from panhypopituitarism, a left homonymous hemianopia and short-term memory

2.2. A Case with a Durable Response
to Treatment
2.2.1. Presentation

Our second patient was a 35-year-old man who presented with
blurred vision that had been present for 3 months. His MRI at this
time, showing a suprasellar mass, is shown in Figure 3.
He underwent craniotomy, via a pterional approach, for resection of the tumor. The pathology is shown in Figure 4. This shows
how ATRT may be suspected on the basis of hematoxylin and
eosin (H&E) staining alone. The diagnosis was confirmed by IHC
for INI1.
A homozygous mutation in SMARCB1 was confirmed on Sanger
sequencing. This was performed on the fresh-frozen, paraffinembedded tissue. The sequencing covered the coding region and

Frontiers in Neurology | www.frontiersin.org
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Figure 4 | Second patient. Immunohistochemistry. (A) Hematoxylin and eosin (H&E) stain, 200× magnification. The tumor comprises two main elements: sheets of
large cells, many with a rhabdoid appearance (top) and small, more primitive-appearing cells (bottom). (B) (H&E) stain, 400×. This shows large cells, many with
rhabdoid features and central mitoses. (C) INI1 stain, 400×. There is no nuclear staining in the tumor cells. A positive control is provided by the endothelial cells in
the vessel at the center, and in other scattered glial and inflammatory cells.

impairment. He also developed a peripheral neuropathy following chemotherapy, most likely due to vincristine.

had an autopsy performed (where we could infer this information). A summary table of all pathologic results is given as
Supplementary Material (worksheet ihc1 in data sheet
1.xlsx). Most of these variables relate to the presence of
certain antigens via IHC.
For IHC, a variety of antibodies and names were used to
assess the presence of various elements. We have standardized
this by recording the antigen being tested. Keratin staining, in
particular, used a range of antibodies and was variously reported
by antibody, by weight of the stained keratin, by keratin type or
at times as “keratin present.”

3. METHODS
3.1. Review of Adult Cases

A literature search was performed using PubMed and Google
Scholar to search for all reported cases of ATRT in adults. All
50 cases were tabulated; this is given as Supplementary Material
(worksheet d1 in data sheet 1.xlsx). Many of these reports
include similar tables; however, we noted a number of inconsistencies in these tables and ours is based on our reading of
the original cases. While many prior authors have reported the
‘classical’ features of ATRT via IHC (see below), we are the first to
tabulate all pathological variables for each case.

3.2. Classification of IHC
3.2.1. Diagnosis of ATRT

Loss of INI1 protein expression (via IHC) is considered a defining
feature of ATRT. Partial deletion of chromosome 22 (detected
via FISH), where the gene (SMARCB1) is located, is considered
as an equivalent test. Both of these tests began to be used widely
after the year 2000. While both tests are considered to have
a specificity of 100% for ATRT (in the appropriate setting), a
negative result does not exclude the diagnosis. Such testing was
reported in 23/50 (46%) of the cases we reviewed.
Prior to the advent of INI1 testing, the diagnosis was suspected
on the basis of the appearance on standard H&E staining. Stain
ing for the “classical” antigens vimentin, epithelial membrane
antigen (EMA), and smooth muscle actin (SMA) was typically
used as confirmatory. Both vimentin and SMA are classically
associated with mesenchymal cells, although this does not imply
a mesodermal origin for such cells. For example, constitutive
expression of vimentin is recognized in arguably the moststudied glial cell line, U-251 (13). Again, a negative test result for
one of these antigens does not exclude the diagnosis.

3.1.1. Clinical Variables

In each case, we recorded age, gender, and location as well as
presence of leptomeningeal metastases (LM) and details of
treatment at initial diagnosis and time of first progression. As
above, a meaningful response to treatment was rare if the dis
ease progressed again after “second-line” approaches. ‘Third-line’
treatments of any kind were exceptional and were not recorded.
The diagnosis of LM was based on clinical details and/or
imaging features, e.g., in the case report of Wang et al. recurrence
was spinal (distal from the original tumor) and appears to have
originated from the leptomeninges on MRI, with subsequent
intra-medullary spread (12).
A number of nominal (categorical) variables were ‘collapsed’ as
this was such a small data set. Location, for example, initially had
15 values; we also analyzed this as a 5- and 3-category variable in
order to look for more general patterns. We also assessed whether
the location was ‘central’ vs. clearly lateralized and whether the
tumor was “next to CSF” based on imaging findings. Similarly, the
extent of resection was considered as an ordinal variable (gross
total > sub-total resection > biopsy) as well as binary (surgery or
not). We analyzed age as binary (i.e., ≥40 years when diagnosed)
as well as a continuous numeric variable.

3.2.2. IHC and Differential Diagnosis

While the diagnosis of ATRT is often quickly suspected in an
infant, the initial differential diagnosis in adults is typically far
wider. Thus, the range of IHC stains employed in adult cases is
far greater and more variable. In total, 81 tests (using IHC) were
performed in our case series. In 19 (23%) cases, the antigen of
interest was tested for in just one specimen.
IHC often included tests for metastasases, germ cell tumors,
neuro-endocrine tumors, and other primary tumors of the

3.1.2. Pathological Variables

We consider here only the pathology at the time of diagnosis
of ATRT. We note that only 2/40 (5%) of patients in our series

Frontiers in Neurology | www.frontiersin.org
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nervous system (glial, medulloblastoma, neuroblastoma). Testing
for a wider range of antigens (in adults vs. children) gives us a
greater insight into the pathophysiology of ATRT.
Other possible differential diagnoses in adults may include
primitive neuroectodermal tumor (PNET), choroid plexus carcinoma, rhabdoid meningioma, and germinoma. However, these
entities generally have more characteristic immunohistochemical
staining patterns with specific markers than the poly-phenotypic
patterns seen in ATRT; also INI1 staining is retained.

3.3.1. Associations

3.2.3. Differential: Rhabdoid Glioblastoma

3.3.2. Survival analysis

We began by looking at the significance of all two-variable associations, using standard measures of strength and significance of
association as follows:
Variable 1
Nominal
Numeric
Nominal

Tumors resembling ATRT, staining with glial fibrillary acidic
protein (GFAP) as well as vimentin, SMA and EMA have been
suggested to represent rhabdoid glioblastoma (GB) rather than
ATRT (7). EMT in the setting of GB appears plausible as an entity
distinct from ATRT. GB with EMT may have been misdiagnosed
as adult ATRT (prior to the advent of testing for INI1), although
this appears unlikely given the clinical and histological findings
in our cases.

Correlation
Cramer’s V
Pearson’s r2
Pearson’s r2

p Value
Chi-squared
t-Test
F-Test

Time-to-event data were analyzed used the proportional-hazards
model (PHM). We looked at the following outcomes:
1. time to progression
2. overall survival
3. time from progression to death (to assess the effects of secondline treatments).
Given the small number of observations and deaths, overfitting was a problem with multivariate PHMs.
Survival times are reported as a median with 95% confidence
intervals (CI). Effect size is given as hazard ratio (HR, relative to
control) and the p value is from the score test (or Wald test for
multivariate models).

3.2.4. Germ Cell Layers

We used IHC to determine the putative germ cell layer of origin
of each specimen. In so doing, we were guided by the tissues that
are known to stain for an antigen under “normal” conditions. The
website accompanying the textbook “Pathology Outlines” was
particularly helpful in this regard (14).
Some stains are not restricted to one germ cell layer. An example is keratin 8, which predominantly occurs in ectodermal tissue
but is also recognized in endodermal tissue (15).

3.3.3. Missing Data

Given such a large quantity of missing data, we tried to compensate in a number of ways:
• Recursive partitioning ‘looks ahead’ at survival to find the best
split for the given data. It is particularly well suited to data sets
where there is near-perfect prediction of outcome by certain
variables. It also allows for a clear ordering of variables in
terms of predictive importance (20).
• “Multivariate imputation by chained equations” uses repeated
regression on the existing variables to estimate missing values.
The technique does have a tendency to strengthen existing
associations rather than developing new insights (21).
• The “nested cohort” design allows for more ‘accurate’ estimates
from a PHM where a covariate is observed for only some
subjects (the cohort). Sampling is stratified by a variable that is
available on all cohort members.

3.2.5. Classification

We thus classified pathological findings into the following groups:
1. ‘ATRT specific’
• ‘Defining’ features (loss of INI1 or del(22))
• ‘Classical’ features (vimentin, EMA, SMA)
2. Ectoderm
• Neural crest (neuronal, glial, neuro-endocrine, melanoma
markers)
• Other ectodermal
3. Endoderm
4. Keratins
5. Mesoderm
• Mesenchymal
• Leukemia/lymphoma markers
6. Germ cell
7. Others (found in a variety of tissues).

This allows for frequency matching on confounders, or
oversampling on the extremes of surrogate [markers] for
exposures, to improve efficiency (22).
That is, this technique allows one to control for major confounders in order to arrive at a more meaningful estimate of effect size
and probability. In our case, we sought to better determine the
effects of various treatments using a sampling scheme based on:

3.3. Quantitative Analysis

Data analysis was performed using R (RRID:SCR_001905)
(16–18). The complete analysis is available as Supplementary
Material (data sheet 2.pdf). Nominal variables are given
as fractions (percentage) and continuous variables as median
(range).
We did not attempt to correct for multiple hypothesis testing,
as the present work is exploratory (19). As the sample size is small,
a priori we considered p values of <0.1 to be potentially worth
reporting.

Frontiers in Neurology | www.frontiersin.org

Variable 2
Nominal
Numeric
Numeric

1. the presence of LM or GFAP staining—as these were the
major confounders of treatment
2. the occurrence of death when the last recorded follow-up
was performed—to try to control for censoring, i.e., the fact
that certain patients were not followed up until death had
occurred.
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4. RESULTS

the presence of nestin in 2/2 cases studied. This is considered a
marker of ‘neuroepithelial stem cells,’ is active in embryogenesis,
and is downregulated in maturity, when expression of neurofilament protein and GFAP occur.
Interestingly, nestin is also expressed in developing muscle
(presomitic mesoderm), to be replaced by desmin in maturity.
Yet, desmin was universally absent in our sample (0/19). Other
markers of mature muscle differentiation were also lacking, as
well as the myogenic regulatory factor MYOD1 (0/2 cases), which
is involved in myogenesis.

4.1. Demographics

The 50 patients reviewed (including the present cases) had a
median age of 32 (18–65); 27 (54%) were females. Of those of
childbearing age, 3/20 (15%) were pregnant when the diagnosis
was made.

4.2. IHC

Some of the more significant findings on IHC are given in Table 1.
As above, the complete table, with explanations, is given in (data
sheet 1.xlsx).
Defining features of ATRT were found in almost all cases
where these were assessed: loss of INI1 in 23/24 (96%), del22q
in 13/15 (87%). It is tempting to consider those cases where
these were absent as “false negatives”; we will return to this in
the discussion.
Of the “classical” features, only vimentin was universally positive (33/33) in our series. Germ cell markers, where assessed, were
uniformly negative. Keratins were variably expressed; keratin 8
was found in the highest proportion of samples assessed, 12/16
(75%). As above, we cannot use this help attribute a germ cell
layer of origin to a specimen (15).

4.2.2. CD34

The hematopoietic system is thought to be derived from mesoderm; as such the presence of markers more typically used in the
diagnosis of leukemia and lymphoma in our sample may at first
appear anomalous. However, CD34 is recognized to occur in
tumors of neuroepithelial origin, particularly those of childhood
(23). It is also expressed on endothelial cells.

4.2.3. CD99

CD99 has been less well studied in CNS tumors. It is recognized to
occur in “primary neuroepithelial tumors of the kidney,” an entity we
believe to be closely related to ATRT (24). It is also present in ependymoma, peripheral primitive neuroectodermal tumor, and in the rare
chordoid glioma, all of which are of neuroepithelial origin (25–27).

4.2.1. Nestin

Markers of neuronal, glial, and neuro-endocrine differentiation
were relatively common (c. 25–75%). Of particular interest is

4.3. Associations

A number of striking associations are given in Table 2. Additional
relationships of significance statistically but of debatable importance biologically are given as in the Supplementary Material as
data sheet 2.pdf.

Table 1 | Immunohistochemistry (IHC) of adult ATRT.
+ve

n

%

‘Defining’ features of ATRT
del(22)(q)
22q11.2 distal deletion
INI1
Integrase interactor 1/SMARCB1/hSNF5

13
1

15
23

87
4

‘Classical’ ATRT markers
vim
Vimentin
EMA
Epithelial membrane antigen
SMA
Smooth muscle actin

33
29
18

33
35
32

100
83
56

Neuronal
S100
nfp
nse
Nestin

13
10
2
2

27
15
6
2

48
67
33
100

12

30

40

6

22

27

20
12

49
16

41
75

0
0

19
4

0
0

3

11

27

2
4

7
5

29
80

Stain

Glial
GFAP

Long name

100% soluble in (NH4)2-SO4
Neurofilament protein
Neuron-specific enolase

Glial fibrillary acidic protein

Neuro-endocrine
Synaptophysin
Major synaptic vesicle protein p38
Keratin
ker
ck8

Keratin (any, including type not specified)
Keratin 8; 52 Da

Mesenchymal
Desmin
Myoglobin
Others
CD34
CD99
p53

Hematopoietic progenitor cell
antigen CD34
Single-chain type-1 glycoprotein
Cellular tumor antigen p53

4.3.1. Demographics and Location

Where the tumor was in or next to the pituitary, 10/11 cases were
in females (91%). The predilection of adult ATRT for this location has been recognized, although the sex-specificity seen here
is novel (28).
Tumors of the spinal cord were associated with increasing age
(Pearson’s r = 0.43, F test p = 0.002).

4.3.2. IHC

Tumors with LM when diagnosed were much more likely to show
GFAP staining (n = 30, chi-squared p = 0.02), implying that glial
differentiation is a major risk factor for this complication.
All tumors that showed synaptophysin staining also stained
for SMA (n = 20, chi-squared, p = 0.03). Synaptophysin was the
only neuroendocrine marker commonly assessed in the sample;
this finding suggests that differentiation along such lines is
associated with a greater tendency to manifest a mesenchymal
phenotype.
Findings regarding neural differentiation were difficult to
interpret. Neurofilament protein (NFP) staining was present in all
female patients (6/6) vs. 4/9 males (chi-square p < 0.1). Strangely,
staining for NFP and neurospecific enolase (NSE) appeared mutually exclusive, i.e., where one was positive the other was negative,
although there were only 4 subjects where both were checked. No
cases where NFP staining was absent stained for GFAP (n = 15).

+ve, positive result, i.e., staining for antigen present; n, number of cases tested; %,
percentage positive/number tested.
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Table 2 | Significant (p < 0.1) two-variable associations.

Table 3 | Percentages of patients without progression, and surviving, at
timepoints following diagnosis.

Chi-square p

Time from diagnosis

ASSOCIATIONS WITH LOCATION

Progression-free (%)

Surviving (%)

46
33
20

76
64
39

6 months
12 months
2 years

Gender

4th Ventricle

Lateral
Ventricle

Pineal

Pituitary

Spinal
Cord

Male
Female

4
3

13
7

2
4

0
10

3
3

0.046

0
5

6
4

4
0

0.007

Intrathecal CT was used in just two cases other than our first
patient. In contrast to our use of liposomal cytarabine, these two
patients were treated with small quantities of methotrexate: three
and one dose(s), respectively (29, 30).

0.043

4.4.3. Treatment at recurrence

Surgery, radiation, and chemotherapy
No
3
14
Yes
3
3
Gender

Lateral

Mid-line

Male
Female

15
9

7
17

Brainstem

Lateral
ventricle

Spinal
cord

12
6

22
4

1
5

Age
18–40
>40

Leptomeningeal metastases at recurrence
No
2
16
2
Yes
6
5
1

When disease re-occurred/progressed, lower proportions of
patients received treatment. Additional SX was attempted in
12/26 (46%), RT in 13/26 (50%) and CT in 11/26 (42%).
0.004

4.5. Survival

The median time to progression (TTP) was 5 months (95% CI
3–18). Overall survival (OS) was 23 months (14–56). Time from
progression until last observation or death (time from progression to death, TPD), in the 27 patients where this was applicable
and available, was 8 months (5–28). The fractions of patients
without progression, and surviving, at various points in time
from diagnosis are shown in Table 3.

0.039

OTHER ASSOCIATIONS
Leptomeningeal
metastases
GFAP

No

Yes

−ve
+ve

16
5

2
7

0.018

4.5.1. Long-term Survivors

Apart from our second patient, two others are reported to have
survived for more than 3 years (31, 32). Unlike our patient, both
re-occurred on multiple occasions following their initial treatment. The first was a frontal lesion that required complete excision 6 times (and once in the contralateral frontal lobe) as well as
receiving radiotherapy, Gamma Knife radiosurgery and systemic
chemotherapy; after 7 years of relapsing disease, she remained
disease free for another 10 years. The other was a parietal lesion
which re-occurred 3 times over the course of 9 years and which
appeared stable 1 year after most recent treatment. Interestingly,
this patients’ tumor was diagnosed and treated as glioma, at
presentation and at first re-occurrence. The diagnosis of ATRT
was subsequently made in retrospect due to the absence of INI1
by IHC in all specimens.

Synaptophysin
SMA

−ve

+ve

−ve
+ve

9
5

0
6

0.031

Neurofilament protein
Gender

−ve

+ve

Male
Female

5
0

4
6

0.094

GFAP, glial fibrillary acidic protein; SMA, smooth muscle actin.

4.4. Treatment
4.4.1. Surgery

Surgery (SX) at diagnosis was a cornerstone of treatment; in only
one case was this not undertaken, where imaging initially suggested vestibular schwannoma and radiotherapy was used instead
(12). Gross total resection (GTR) was reported in 10/43 (23%) of
cases. This was most common for those tumors located next to a
lateral ventricle. Subtotal resection was most common for tumors
of the pituitary and pineal gland.

4.5.2. Clinical Variables and IHC

4.4.2. Adjuvant Treatment

4.5.3. Treatments

Significant predictors of survival in PHMs are shown in Table 4.
Of note, LM and GFAP staining appear as significant predictors in almost all of these models. While LM and GFAP are
correlated, LM appears to be the more important predictor,
particularly in multivariable PHMs. The effect of LM on OS is
shown in Figure 5.

Radiotherapy (RT) was undertaken in 33/42 (79%) and systemic
chemotherapy (CT) in 17/42 (40%). Cranio-spinal irradiation
(CSI) was performed in 5/34 (15%). All three approaches (SX,
RT, and CT) were used in 15/42 cases (36%). This multimodality
approach was most commonly used for those tumors next to a
lateral ventricle (Table 2).
Frontiers in Neurology | www.frontiersin.org
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and multimodality treatment (SX, RT, and CT, HR = 0.3) were
significant predictors. Both GTR and CT were significant predictors in the multivariable PMH for OS.
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The effects of the most common initial treatments on OS,
when controlling for LM and GFAP (and death, in both cases),
are shown in Table 5.

Table 4 | Leptomeningeal metastases and GFAP staining are significant
predictors in most proportional-hazards models.
Variable

n

HR

Uni-variable
TTP

OS

TPL

Score
RT
SX
GFAP
LM
GTR
LM
GFAP
SX
SRC
Pregnant
GTR
LM
GFAP

33
33
22
33
33
41
27
40
40
18
39
27
18

0.13
Ordinal
1.9
2.4
0.86
4.6
3.1
Ordinal
0.25
4.5
0.55
6.7
7.5

Multivariable
TTP
n = 21, e = 14

OS
n = 27, e = 15

TPL
n = 18, e = 14

p

5. DISCUSSION

<0.01
0.02
0.19
0.04
0.75
<0.01
0.04
<0.01
0.02
0.05
0.3
<0.01
<0.01

5.1. Pathogenesis

5.1.1. Location at Diagnosis and Implications
for Anatomical Origin

ATRT in adults has a predilection for mid-line structures, particularly the pineal and pituitary glands. These are circumventricular
organs, which are now recognized as a source of neural stem cells
in adults (33).
ATRT may be said to be the prototypical tumor of infancy, in
having the earliest onset and highest perinatal incidence of such
tumors. Tumors of infancy in general are thought to arise from
cells that have not completed the process of terminal differentiation and continue to undergo hyperplasia from the latter half of
pregnancy to age 3 or so (34).
Our case series suggests that there remains a pool of slowly
dividing ‘ectodermal stem cells’ in at least some of these circumventricular organs that remains capable of acquiring carcinogenic
mutations throughout most of adulthood (35). The proximity of
these organs to CSF may explain the close association of these
tumors with such locations and their tendency to develop LM. Of
note, when ATRT occurs in a cerebral lobe, it typically appears in
communication with a lateral ventricle.
We suspect that in many cases the tumor has already spread
via CSF prior to diagnosis. This would help to explain the proposal of such entities as “primary diffuse cerebral leptomeningeal
ATRT” and “ATRT arising from the acoustic nerve”; these structures appear unlikely to be points of origin for ATRT (12, 36).
The strong association between pituitary involvement and
female gender is consistent with the greater mitotic activity
of the pituitary in females throughout the lifespan (37). We
acknowledge there remains much work to be done in this area.

Wald
LM
RT
GTR
GFAP
LM
GFAP
GTR
CT
RT
LM
GFAP

21

27

18

4.4
0.32
0.41
2.3
5.5
2.4
0.27
0.24
1.5
3.7
2.4

0.01
0.13
0.20
0.18
0.02
0.25
0.07
0.03
0.6
0.4
0.6

p values: for uni-variable models = score test; for multivariate models = Wald test.
HR, hazard ratio; TTP, time to progression; OS, overall survival; TPL, time from
progression to last follow-up/death; n, number of observations; e, number of events
(progression or death); RT, radiotherapy; SX, surgery (ordinal; HRs not shown);
GFAP, glial fibrillary acidic protein; LM, leptomeningeal metastases; GTR, gross total
resection (vs. other value for surgery); SRC, surgery, radiation, and chemotherapy; CT,
chemotherapy.

In assessing the effects of treatment, we acknowledge that
we are not “comparing like with like,” i.e., patients for whom a
certain treatment is not possible will be expected to have a worse
outcome. Regarding surgery, GTR is generally the goal, where
possible; those for whom this is not feasible will tend to have a
worse prognosis, no matter the approach to surgery. Similarly,
those for whom CT is impossible will tend to have poorer survival
outcomes. However, significant comorbidities or disabilities due
to disease (thus limiting the use of CT) were exceptional at the
time when CT was commenced.

5.1.2. IHC and Implications for Cell Type of Origin

As summarized in Table 1, findings on IHC suggest a tumor
of ectoderm origin with EMT. For example, the combination
of EMA (epithelial, 83%), vimentin (mesenchymal, 100%), and
complete absence of markers of mature mesenchyme (desmin,
myoglobin, 0%) are characteristic of such a phenotype.
In this regard, the name “ATRT” is somewhat misleading
in that it is clearly not a teratoma and does not contain elements originating from mesoderm or showing skeletal muscle
differentiation.
Classification of IHC by cell type and germ layer in adult
ATRT has also been undertaken by Raisanen et al. (38). Their
table is similar to our own, albeit with a smaller sample size. The
authors do not attempt to infer any implications for pathogenesis
from their table.

4.6. Recursive Partitioning

The most important predictor of OS was clearly LM; this is shown
in Figure 6. When LM was excluded from the analysis, multimodality therapy (SX, RT, and CT) became the most significant
variable (Supplementary Material, data sheet 2.pdf).

4.7. Multiple Imputation and
“Nested” PHM

5.1.3. Germline Mutations and del22q

Applying these techniques to the potentially important predictors already identified tended to confirm the results above (data
sheet 2.pdf).
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Figure 5 | Overall survival is significantly worse in patients with leptomeningeal metastases (LM) at the time of diagnosis. Time scale is shown in months.
Hazard ratio 4.4, score test p = 0.0005.

Table 5 | Chemotherapy is the most important predictor of overall survival,
when controlling for leptomeningeal metastases and GFAP staining (using
‘nested cohort’ proportional hazards models).

LM
n = 39, e = 24
GFAP
n = 27, e = 15

Variable

HR

p

CT
RT
GTR
CT
RT
GTR

0.45
0.56
0.43
0.31
0.64
0.31

0.09
0.3
0.3
<0.01
0.5
0.1

HR, hazard ratio; GFAP, glial fibrillary acidic protein; LM, leptomeningeal metastases;
n, number of observations; e, number of events (deaths); CT, chemotherapy; RT,
radiotherapy; GTR, gross total resection (vs. other value for surgery).

22q. The only case we reviewed where this seemed likely was
our case with a prolonged response to treatment. The patent had
macrocephaly and a history of spinal schwannoma as a teenager.
None of the other reported a personal or family history of
dysmorphism or of tumors seen in the rhabdoid-predisposition
syndrome.
Nonetheless, it has been recognized that germline mutations
in SMARCB1 germline mutations are not always inherited and
unaffected adult carriers are recognized (40). In this series of
100 patients, those with germline mutations tended to present at a much younger age, at a median of 5 months (range
birth—5 years) vs. 18 months (birth—17 years) for those with
acquired mutations. However, in 4 of 7 cases of inherited mutations, the parents appeared completely unaffected. The authors
also recognize germline/gonadal mosaicism in their sample,
i.e., the mutation must have been present within parental gametes
but not somatic cells.

Figure 6 | Recursive partitioning analysis shows LM to be the most
important predictor of overall survival. Abbreviations: LM, leptomeningeal
metastases; SRC, surgery, radiation and chemotherapy (≥0.5 means all
modalities employed); Sx, Surgery; gtr, gross total resection; sx, surgery
(extent unspecified); str, subtotal resection; bx, biopsy; none, no surgery.
Key: circles, branching nodes; squares, terminal nodes; green, better
outcomes; pink, worse outcomes; upper, no. predicted event rate;
lower, no. no. events/no. at risk.

(distal 22q11 microdeletion syndromes) (39). None of the cases
of ATRT in this series, including our own, had germline analysis
performed to look for a mutations or deletion of chromosome

Frontiers in Neurology | www.frontiersin.org
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Such germline mutations result in a phenotype known as
“rhabdoid predisposition syndrome.” In addition to ATRT, carriers appear predisposed to rhabdoid tumors (renal and extrarenal), PNET, medulloblastoma, choroid plexus carcinoma and
schwannoma (41). These authors also suggest the mutation as a
cause for cases of Li–Fraumeni-like syndrome (patients with a
childhood cancer or “sarcoma” aged <45 and a family history of
cancer at a young age, in those lacking germline TP53 mutations).
Thus, we recommend somatic analysis in addition to analysis
of the tumor, even in adult patients (42). Analysis of parental
somatic and germline DNA also appears desirable.

Loss of function of these chromatin remodeling complexes
enables the development of the ‘open’ structure required for EMT.
It remains unclear why loss of INI1 leads to diverging epigenetic
phenotypes.

5.2. Clinical Trials

Ongoing and recently completed trials for this condition are
tabulated in the recent review by Fruhwald et al. (3). The dearth
of clinical trials enrolling adults >21 years old, just seven at the
time of writing, is shown in Table 6.
As a rare condition, even in children, there is some justification for ‘lumping’ ATRT with similar tumors. This is particularly
rational when the intervention is relatively non-specific, e.g.,
radiotherapy, traditional ‘cytotoxic’ chemotherapy (and soon,
perhaps, immunotherapy).
In the case of more ‘targeted’ treatments, the pool of analogous diseases will be much smaller. Two of the seven trials may
be said to be target aspects of the biology of ATRT. It is striking
that the trial of alisertib aims to inhibit aurora kinase A, an
enzyme that has been implicated in EMT. This trial includes
malignant rhabdoid tumors (MRT), which show EMT but do
not lose INI1 protein (46). MRTs, as well as rhabdoid tumors
of the kidney (also showing EMT), are included in the trial of
tamezostat (an EZH2 inhibitor). While beyond the scope of the
current work, we suggest that the term “rhabdoid” is synonymous with EMT. Interestingly, the trial of tamezostat considers
other tumors lacking INI1 to be sufficiently similar to be worth
including.
The other five trials that include ATRT are relatively ‘nonspecific’ and compensate for its low incidence by combining
it with other ‘serious’ tumors, typically also of childhood. For
example, four of five include PNET and medulloblastoma.

5.1.4. INI1, del22q, and Epigenetic Subgroups

The only consistent genetic change in these tumors appears to
be loss of INI1 due to SMARCB1 mutations (which are variable)
(4, 43). Mutation of SMARCA4 is recognized as an alternative
inciting event in rare cases, perhaps accounting for the single
patient in our series with preserved INI1 expression. The lack
of other consistent candidate oncogenic mutations has led to the
recognition that epigenetic changes are crucial to pathogenesis.
Three such epigenetic subgroups are now recognized (44). There
were no adults in this recent work characterizing subgroups (age
range: birth to 9.5 years). The subgroups are named based on the
pathways most commonly upregulated, here shown with some of
the genes whose expression is characteristically increased:
ATRT-TYR

Melanogenesis pathway

ATRT-SHH
ATRT-MYC

Hedgehog pathway
MYC pathway

EZH2, DNA methyltransferases
(DNMTs), CCND1, VEGFA, ERBB2
EZH2, DNMTs, CDK6
MYC, HOX genes, EZH2, DNMTs,
ERBB2

Phenotypically, the ATRT-TYR subgroup is strongly associated with a supratentional location vs. ATRT-MYC; ATRT-SHH
appears in both locations.
Further characterization of phenotype by subgroup may
be facilitated by preserving the methylation status of DNA in
the tumor specimen. We suggest that fresh-frozen material be
obtained for this purpose where practical. Technical advances
continue to make methylation profiling more practical in formalin fixed, paraffin-embedded samples.

5.3. Treatment

As ATRT is primarily a disease of infancy, co-ordination of
treatment between pediatric and adult oncology services appears
appropriate.

5.3.1. Chemotherapy

ATRT usually occurs before CSI can be given safely, i.e., in those
aged <3. Thus, CT has traditionally been a cornerstone of treatment. We suggest that a primary guiding factor be penetration
into CSF (given the high prevalence of LM) as well as into the
intraparenchymal tumor. As these tumors tend to disrupt the
blood–brain barrier (BBB) and are often next to parts of the brain
with no BBB, penetration of CT into normal brain parenchyma
does not appear to be of prime concern.
In the rare cases when ATRT is localized and can be completely
excised, local RT appears appropriate; arguably, a protocol similar
to that used for glioblastoma can be adopted in such cases.
The most common approach to CT typically involves cytotoxic
and relatively non-specific agents. Ifosfamide, carboplatin, and
etoposide (ICE) was the most common regimen in our series, a
protocol typically used for sarcoma and lymphoma. These agents
have reasonable brain and CSF penetration (47–49). However,
given the grave prognosis of this condition, a more aggressive
approach appears warranted in adults, as in our second case.

5.1.5. Chromatin Remodeling and EMT

EMT is known to result in a more ‘open’ chromatic structure (9).
This is necessary to facilitate de-differentiation, i.e., the transcription of mRNA, which is typically unavailable to the differentiated
epithelial cell. This includes a shift in energy (ATP) production
from oxidative phosphorylation to glycolysis. This is necessary
for the supply of energy of biosynthetic precursors, of a balanced
redox status and appears necessary to maintain the undifferentiated state.
Chromatin remodeling complexes such as INI1 have been
implicated in various cancers (45). INI1 is now recognized as a
tumor suppressor, due to its mutation in tumors including choroid
plexus carcinoma, medulloblastoma, primitive neuroectodermal
tumor, and chronic myeloid leukemia. INI1 is a member of the
SWI2/SNF2 remodeling complex, which is ATP dependent.
Frontiers in Neurology | www.frontiersin.org
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Table 6 | Ongoing clinical trials enrolling patients aged >21.
NCT ID

Agent

MOA

CA

MC

Age

Phase

n

http://clinicaltrials.gov/
show/NCT02601950

Tazemetostat

EZH2 I

No

Yes

>16

2

150

Cohorts
rhabdoid: ATRT
MRT
RTK
Refractory synovial sarcoma
+ SS18-SSX rearrangement
INI1 −ve: EMPNST
EMC
Myoepithelial Ca
Chordoma
RMC
Epithelial sarcoma

http://clinicaltrials.gov/
show/NCT01505569

1–3 cycles:
Ifosfamide
Etoposide
→Carboplatin
→Thiotepa

Autologous
peripheral
blood
stem cell
transplant

Yes

No

<70

SOC

20

r/r solid tumor
CNS tumor: ATRT
PNET age <3
High risk MB age <3
MB age <8 months
Anaplastic MB
Germ cell tumor

http://clinicaltrials.gov/
show/NCT00445965

131

I-3F8 Ab

Ganglioside
GD2

No

No

Any

2

131

CNS/LM tumor
GD2 +ve

http://clinicaltrials.gov/
show/NCT00983398

Intra-arterial:

Yes

No

1–30

1/2

55

r/r CNS ATRT
embryonal PNET
tumor: MB
Medulloepithelioma
Pineoblastoma
Ependymoblastoma
Germ cell tumor

No

Yes

<22

2

180

ATRT (with chemoTx)
r/r: ATRT
MRT

Yes

No

<22

2

10

r/r: ATRT
PNET
MB
Ependymoma

Yes

No

1–21

1/2

18

r/r: ATRT
PNET
MB
Ependymoma
CPCa

Melphalan
Carboplatin
Mannitol
Thiosulfate

Alkylating
DNA repair
Osmotic
Adsorbent

http://clinicaltrials.gov/
show/NCT02114229

Alisertib

Aurora A I

http://clinicaltrials.gov/
show/NCT02684071

Intraventricular methotrexate
with systemic:
Topotecan
Cyclophosphamide

Topoisomerase I
Alkylating

Methotrexate via 4th ventricle

Anti-folate

http://clinicaltrials.gov/
show/NCT02458339

NCT ID, National clinical trials identifier; CA, commercially available; MOA, mode of action; MC, multi-center (i.e., ≥3 sites); n, number of patients (estimated accrual); Ab, antibody;
I, inhibitor; EZH2, enhancer of zeste homolog 2 (enzyme); SOC, standard of care/protocol; r/r, recurrent/refractory (progressive); MRT, malignant rhabdoid tumor; RTK, rhabdoid
tumor of the kidney; EMPNST, epithelioid malignant peripheral nerve sheath tumor; EMC, extra-skeletal myxoid chondrosarcoma; RMC, renal medullary carcinoma; PNET, primitive
neuroectodermal tumor; MB, medulloblastoma; CPCa, choroid plexus carcinoma.

Once a decision on the use of RT has been made for a patient
with ATRT, factors such as timing, dosing, and technique need
to be considered.
Chen et al. reported improved disease-free survival in patients
who had a total dose more than 50 Gy (55). Significant improvement in median survival was reported in patients who had a
shorter interval between SX and RT. RT delivered early vs. latein
the course of treatment has also been associated with improved
survival (11).
Proton therapy may be especially attractive in younger patients,
in order to minimize the risk of late complications. Encouraging
results with local conformal proton therapy have been reported

5.3.2. Radiotherapy

Several reports demonstrated the beneficial role of adjuvant
RT after surgical resection in patients with ATRT (11, 50, 51).
However, RT is a significant challenge in those younger than
3 years old (52).
The benefit of combining RT with SX in ATRT has been shown
by Lau et al. (53). In a sample of 171 pediatric and 3 adult cases,
they report an increase in median survival from 1.9 ± 0.4 to
5.9 ± 0.7 years in those who had RT in addition to SX. Buscariollo
et al. confirmed the value of RT in another retrospective series,
this with 144 patients, where median survival improved from 6
to 34 months (p < 0.001) (54).
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by Bernstein et al. (56). Nine of ten patients with ATRT (with
a median age of 1.8 years) had no evidence of disease, with a
median follow-up of 27.3 months.
As distal relapse is associated with higher mortality and as the
majority of distant relapses occur within the CNS, CSI is recommended is those older than 3 years old: 23.4 Gy to the neuraxis
(with 54 Gy to the tumor bed) is recommended inpatients older
than 3 years old. Younger patients have been treated using either
no adjuvant RT or local-only RT, with a trend toward improved
survival with the addition of RT.

adults. The use of stem-cell rescue allows for the use of more
aggressive chemotherapeutic regimens than has hitherto been
the case.

CONSENT
Written, informed consent was obtained from both patients
specifically for the publication of these case reports.
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Promising results have been already been shown in children >3
with PNET undergoing CSI followed by high-dose CT and in
the setting of recurrent CNS tumors (57, 58). Stem-cell rescue
was required with these more aggressive regiments, either from
peripheral blood or bone marrow. Given its known role as a
radiosensitizer and excellent brain and CSF penetration, the use
of temozolomide during radiotherapy also appears reasonable
(59). Early use of intrathecal chemotherapy also appears rational.
As it is well tolerated in long-term use, it may also be an acceptable approach in those patients who would not tolerate more
aggressive forms of CT.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at http://journal.frontiersin.org/article/10.3389/fneur.
2017.00247/full#supplementary-material.
Additional information is provided in supplemental files:
• data sheet 1.xlsx A spreadsheet with the following
worksheets:
• d1 Data set used for analysis.
• k1 Key to data set.
• ihc Immunohistochemistry.
• data sheet 2.pdf Statistical analysis.

6. CONCLUSION
ATRT in adults carries a grave prognosis, particularly in those
cases with leptomeningeal spread. We postulate that ATRT is a
tumor of neuroectodermal origin that demonstrates mesenchymal transition.
Our cases indicate the possibility of improved outcome with
more aggressive therapy. CSI should always be considered in

Case reports and case series reviewed, but not specifically cited
above (60–89).
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